Introduction
============

Head and neck cancer (HNC) is the 6th most common malignancy worldwide, most patients presented advanced stage when diagnosed, which was characterized by low 5-years survival rate and poor prognosis [@B1]-[@B3]. The traditional treatments for HNC are surgery, radiotherapy and chemotherapy. Owing to the complexity of structure and the need for organ preservation, these traditional treatments for HNC have many limitations. Cancers with invasion to deep and important location or with multiple distant metastases are unresectable [@B4], [@B5]. Moreover, surgical treatment would cause a significant decrease in physical function and cosmetic impairment. Radiation therapy often induces many adverse effects such as oral mucositis, osteoradionecrosis, tissue fibrosis and salivary gland dysfunction [@B6], [@B7]. Therefore, novel therapies with stronger effect and lower toxicity are urgently needed.

Since most HNCs are insensitive to anticancer drugs, chemotherapy alone is not a preferred treatment for HNC [@B8]. It is usually combined with radiation therapy. Early practice was mainly focus on intra-versus chemotherapy combined with radiotherapy (IVCRT), although there are certain advances by employing IVCRT, the results of HNC patients are still unsatisfactory, due to low drug level in cancer site and high drug level in circulatory system. In recent years, intra-arterial chemotherapy combined with radiotherapy (IACRT) for HNC attracts many attentions, which was proved to get favorable results in many clinical trials, especially after advanced angiographic techniques developed, permitting the infusion of drugs superselectively into tumor feeding arteries [@B9], [@B10]. The greatest advantages of IACRT are increased drug concentration at the tumor bed and mild systemic toxicity due to relatively low level of the drug in blood circulation [@B11]. Robbins and his co-workers inserted a catheter into femoral artery with cisplatin, which reported to achieve high percentage of local control without increasing adverse effects in advanced carcinoma of the head and neck [@B12], [@B13]. Mitsudo et al. achieved high complete response (CR = 95.8%) and 3-year overall survival (OS = 81.5%) through using retrograde superselective IACRT for tongue cancer [@B14]. Although many studies showed favorable outcomes, there are still some controversies. Some investigations only obtain poor CR rate (38.5%) and lower 5-year OS rate (39.5%) [@B15], [@B16]. Therefore, the exact efficacy of IACRT remains controversial, especially for cancers in different stages, which may be more valuable for clinicians.

Therefore, this meta-analysis was conducted to evaluate the efficacy and safety of IACRT on the treatment of HNC patients. Furthermore, by dividing patients according to the stages, we attempted to analyze IACRT efficacy in different stage HNC, which may provide the summarized and evidence-based information for clinicians in treating HNC patients.

Methods
=======

This systematic review and meta-analysis was complied with PRISMA Statement [@B17].

Search strategy
---------------

We manually searched and selected documents with the following search terms: "radiation therapy" and "intra-arterial chemotherapy" or "intra-arterial drug administration" and "mouth cancer" or "mouth carcinoma" or "tongue carcinoma" or "mouth tumor" or "salivary gland tumor" or "parotid gland tumor" or "tongue tumor" or "pharynx tumor" or "tonsil tumor" or "oral cancer" or "oral tumor" or "mouth squamous cell carcinoma" or "gingival carcinoma" or "carcinoma of gingiva" or "oropharynx carcinoma" or "head and neck cancer" or "head and neck tumor" from PubMed, Embase, Cochrane Library, Web of Science and PMC databases. Additionally, we search original published articles, reviews, references cited in the relevant review articles, conference abstracts and the publications of experts up to August 2019 to find the related articles.

Study selection
---------------

All literatures were manually read and screened in dependently by two reviewers (Y. Huang and R.L. Xiang). Any discrepancies between the two reviewers were solved by a consensus. Animal studies and non-English articles were excluded. If the review includes raw data, detailed examination of the full text will lead the studies to be included or excluded. If there were duplicate studies, we choose articles published most recently or providing more detailed information. If review contains raw data, it will also be included.

Data extraction and quality assessment
--------------------------------------

An investigator used a pre-designed structure table to extract data from each eligible study, another investigator independently reviewed the data to ensure accuracy. Eligible trials have to satisfy the Participants, Intervention, Comparison, Outcomes, and Setting (PICOS) criteria: (1) Participants: HNC patients, (2) Intervention: intra-arterial chemoradiotherapy, (3) Comparison: no comparison, (4) Outcomes: CR or OS of IACRT therapy, (5) Setting: most studies are retrospective studies. The studies of intra-arterial chemotherapy (IACT) without radiotherapy were not included. Additionally, we included one RCT and three prospective studies, but only data from the IACRT group were used.

Since most of the studies included were single-arm cohort studies, we used the CASP-Cohort-Study-Checklist to assess the quality of the studies. Two authors (Y. Huang and R.L. Xiang) assessed the quality and risk of bias in the eligible studies independently. Disagreements were solved through discussion and reevaluation.

Statistical analysis
--------------------

We evaluated therapeutic effect of IACRT in the treatment of HNC by assessing CR and OS with their 95% credible interval from included trials, and drawing plotted forest map according to the results. We also performed a subgroup analysis to assess the impact of IACRT to different stage HNCs. A combined analysis of OS in the graded patients was conducted including the 3-year OS of stage III and stage IV cancers as well as the 5-year OS of T3 and T4 cancers. Furthermore, we calculated toxicity incidence with 95% credible interval of enrolled reports to assess the safety of IACRT. All statistical analyses were conducted by using Stata14 statistical software, and a *P* \< 0.05 was considered to have statistical significance. *I^2^* statistics were used to measure statistical heterogeneity. If *I^2^* \> 50%, a random-effect model was used, otherwise, a fixed-effect statistical model was used. Stata 14 Egger\'s test and Begg\'s funnel plot were used to assess publication bias, *P* value lower than 0.05 were judged as statistically significant, indicating that the study has publication bias.

Results
=======

Eligible studies
----------------

A search in PubMed, Embase, Cochrane Library, Web of Science and PMC databases yielded a total number of 3306 articles. After removing duplicated and irrelevant records, only 128 full-text articles remained for eligibility. We then excluded the following studies: review article, nonhuman study, study design, insufficient information for meta-analysis. Finally, 34 papers were identified for the present meta-analysis (Fig. [1](#F1){ref-type="fig"}).

Study characteristics
---------------------

The meta-analysis included 34 studies consisting with a total number of 1890 patients. Among which 27 studies were from Japan, 3 studies were from Italy, others were from USA, Korea, Germany and Macedonia, respectively. Ten types of HNCs were investigated in this meta-analysis, including squamous cell carcinoma (SCC) of tongue, gingiva, mouth floor, buccal, palate, larynx, oropharynx, maxillary sinus, paranasal sinus and nasal natural killer/T-cell lymphoma (NNKTL). Among these records, 30 were retrospective studies, 3 were prospective study, only one was randomized controlled trial (RCT). Moreover, 5 studies provided 5-year OS rate, 9 studies reported both 5-year OS and CR rates, 10 studies assessed both 3-year OS and CR values, and just 5 studies estimated all 3-year OS, 5-year OS and CR values. The detailed information of each study was listed in Table [1](#T1){ref-type="table"}.

Results of individual studies and data synthesis
------------------------------------------------

### Complete response (CR)

CR refers complete clearance of the lesion after treatment, which directly reflects the clinic efficiency of cancer treatment. Twenty-nine studies containing 1382 patients were enrolled to evaluate CR value, in which, 24 studies presented high CR rates ranging from 0.71-1.00. Furusaka et al. achieved 96%, 86% and 94% CR rates in SCC of tongue, hypopharyngeal piriform sinus and anterior oropharyngeal wall, respectively [@B20]-[@B22]. Additionally, 73% and 84% of CR rates were reported by Fuwa et al. using carboplatin and cisplatin, respectively [@B16], [@B23]. Only 2 studies had relatively lower CR rates of 0.22 (95% CI: 0.03-0.42) and 0.38 (95% CI: 0.25-0.52). The combined CR value was up to 0.81 (95% CI: 0.76-0.86, *P* \< 0.001). Heterogeneity in these studies was higher than 50% (*I^2^* = 87.8%), so we used a random-effect model (Fig. [2](#F2){ref-type="fig"}).

### Overall survival (OS)

OS was defined as the time from the commencement of treatment until death or last follow-up time, which largely represents treatment efficacy. The 3-year OS rate was calculated from 15 studies including 836 subjects. As showed in Fig. [3](#F3){ref-type="fig"}A, the highest 3-year OS was 0.94 (95% CI: 0.85-1.04), and the lowest one was 0.48 (95% CI: 0.23-0.74). Despite high heterogeneity (*I^2^* = 81.9%), the merged 3-year OS rate was still up to 0.75 (95% CI: 0.68-0.82, *P* \< 0.001). Additionally, a random-effect model was employed (Fig. [3](#F3){ref-type="fig"}A). We further conducted subgroup analysis on the effect of IACRT on 3-year OS ratio of stage III and stage IV HNC. Data were extracted from 3 studies consisted of 140 patients in stage III and 177 patients in stage IV HNC, who underwent IACRT. The combined 3-year OS rate of stage III and stage IV were 0.75 (95% CI: 0.53-0.97, *P* \< 0.001) and 0.52 (95% CI: 0.37-0.66, *P* = 0.025), respectively. The heterogeneity of stage III and stage IV HNC were 91.6% and 73.0%, respectively. Therefore, random-effect model was used (Figs. [3](#F3){ref-type="fig"}B and [3](#F3){ref-type="fig"}C).

Twenty studies with 1185 samples were included in the 5-year OS assessment, among them, 5 studies also provided 3-year OS rate. As showed in Fig. [4](#F4){ref-type="fig"}A, the 5-year OS rate was scattered among 0.37-0.90, whose synthesis value was 0.68 (95% CI: 0.61-0.75, *P* \< 0.001) just litter lower than that of 3-year OS, this indicated that there was no difference between 3-year OS and 5-year OS by using IACRT. In addition, we also analyzed the 5-year OS in T3 and T4 subgroups. Three studies with 75 patients and 5 studies with 125 patients were included in T3 and T4 group, respectively. It should be noted that some studies classified T4 stage more detailed including T4a and T4b. Therefore, we merged the OS ratio of T4a and T4b of these studies in advance, and then used the combined OS value to merge with other studies. The combined 5-year OS rate of T3 was 0.87 (95% CI: 0.73-1.01, *P* = 0.028), however, the 5-year OS rate was 0.53 (95% CI: 0.42-0.63, *P* = 0.286) in T4 subgroup, which was much lower than T3 stage. A random-effect model was adopted in T3 subgroup as *I^2^* = 72%. However, a fixed-effect statistical model was used in T4 subgroup for low heterogeneity (*I^2^* = 20.1%) (Figs. [4](#F4){ref-type="fig"}B and [4](#F4){ref-type="fig"}C).

### Toxicity

Toxicity can reflect the safety characteristic of treatment. It is regarded as an essential indicator of prognosis. Therefore, we extracted all side-effect data from 34 studies, which mentioned nearly 70 side-effect reactions. We reclassified and extracted 10 kinds of toxicities after excluding the side effects mentioned in less than three studies such as hyperuricemia, renal disorders, gastrointestinal diseases and osteoradionecrosis. Oral toxicities including oral diseases reported by 10 studies and mucositis reported by 21 studies were the major complications with the high incidence of 0.51 (95% CI: 0.27-0.76) and 0.59 (95% CI: 0.42-0.76), respectively. The next two toxicities were dermatitis (0.43, 95% CI: 0.23-0.63) and leukopenia (0.40, 95% CI: 0.30-0.50), The incidence rates of general condition, anemia, nausea/vomiting and thrombocytopenia were lower than 0.35. Fever and hepatic dysfunction were the last two toxicities with the lowest incidence rates of 0.12 (95% CI: 0.06-0.18) and 0.06 (95% CI: 0.02-0.11), respectively (Table [2](#T2){ref-type="table"}). All these adverse effects were manageable and reversible. Moreover, we mapped the forest graph based on the incidence rates of these 10 toxicities (Fig. [5](#F5){ref-type="fig"}).

Risk of bias across studies
---------------------------

The *P* value of Egger\'s test in CR combination was less than 0.001, indicating that significant publication bias exists. Therefore, we used trim-fill method and found that by filling 6 studies, the bias can be eliminated. The effect value of CR was 0.748 (95% CI: 0.680 - 0.816) (Fig. [6](#F6){ref-type="fig"}A). However, we haven\'t found suitable study yet. The Egger\'s test of 3-year OS showed no significant publication bias for *P* = 0.969, and the Begg\'s funnel plot was shown in Fig. [6](#F6){ref-type="fig"}B.

Discussion
==========

In the current systematic review and meta-analysis, 34 clinical trials including 1890 subjects diagnosed as HNC were enrolled. We assessed the efficacy of IACRT by calculating CR and OS rates in HNC patients underwent IACRT. The combined CR, 3-year OS and 5-year OS rates were all favorable. However, when assessing OS by classification of cancer into detail stages, the 3-year OS rate of stage III was higher than stage IV. Simultaneously, the 5-year OS rate of T3 patients was much higher than T4 patients. Additionally, oral diseases, mucositis, leukopenia and dermatitis were the common but reversible toxicities of IACRT. Therefore, we concluded that IACRT is efficacious for HNC which not only increases patient\'s survival rate, but also improves patient\'s quality of life.

In recent decades, IACRT was introduced to improve the outcome of patients with advanced HNC. Compared to conventional therapy, it is a friendly approach for preservation of organ and its function. Moreover, it can increase tumor responsiveness by increasing drug concentrations at the tumor site, meanwhile minimize the dose-limiting systemic side effects of drugs [@B48]-[@B50]. Concurrent combination of arterial infusion therapy with high dose of cisplatin and radiotherapy achieved 80% of CR in T3 and T4 HNC patients, which was only 61% in systemic chemotherapy combined with radiotherapy [@B12], [@B13]. Another study analyzed the therapeutic results of retrograde superselective intra-arterial chemoradiotherapy in 118 patients with tongue cancer, and got a CR of 0.96 and a 3-year OS of 0.82, indicating that retrograde superselective IACRT for tongue cancer provided excellent overall survival and locoregional control [@B14]. Even though, poor tumor response and survival still exist in some studies. Kondo et al. achieved only 0.22 of CR rate in patients with T3 or T4 oral squamous cell carcinoma [@B28]. The 3-year OS reported by Fujishiro et al. was 0.48 in maxillary sinus carcinoma [@B19]. Therefore, whether IACRT has a better prognostic effect on HNC patients remains controversial. In the present study, we evaluated the efficacy of IACRT by assessing CR, 3-years OS and 5-years OS in HNC patients. The combined CR ratio, 3-year OS and 5-year OS rates were 81%, 75% and 68%, respectively, indicating that IACRT can get good control and provide high survival rates for HNC.

In clinical practice, cancers in different stages were treated by different therapies. For patients with early stage HNC, the treatment strategy is preferentially surgery. For the advanced HNC, a combined-modality treatment with surgery and radiotherapy or chemotherapy is clinically used. Therefore, we further analyzed 3-year OS rates in stage III-IV HNC and 5-years OS rates in T3-4 HNC. The 3-year OS in stage III and stage IV cancer were 75% and 52% respectively. Identically, 87% and 53% of 5-years OS were achieved in the patients with T3 and T4 HNC, respectively. A study on 201 patients with tongue SCC reported 64% 3-year OS rates in stage III and 37% in stage IV cancer by systemic chemoradiotherapy [@B51]. Mroueh et al. compared 5-year OS of operation therapy combined with radiotherapy (OT + RT) and operation therapy combined with chemotherapy (OT + CT) among 360 patients with stage I-IV tongue cancers, and obtained a 5-year OS rate of 61% in OT + RT group, and the 69% and 51% 5-year OS rates for patients with stage III and IV in OT + CT group [@B52]. Although these results were incomparable, the OS rate of the present study was better than radiotherapy or systemic chemotherapy. Moreover, a randomized trial on 140 HNC patients (oropharynx, maxillary antrum and intra-oral) compared the efficacy of IACRT and RT alone. The overall 5-year survival was 43% in the IACRT group and 25% in the group treated with radiation alone [@B53]. These findings indicated that IACRT was an efficient approach to improve outcomes of HNC patients, especially for the patients with stage III or T3 cancers.

Traditional systemic chemotherapy or intravenous chemotherapy increases the concentration of drugs in blood, causing myelosuppression, leukopenia, thrombocytopenia, nausea, vomiting and damage to multiple organs [@B54]-[@B56]. Some studies found no differences in locoregional control or overall survival between IACRT and IVCRT, but renal toxicity and late dysphagia were worse in IVCRT group comparing with IACRT [@B57]. Kobayashi et al. compared clinical outcomes and patient\'s quality of life between IACRT and surgery combined with radiotherapy in patients with tongue and mouth floor SCC, IACRT showed superior to surgery plus radiotherapy in terms of the survival rate and quality of life, indicating that IACRT should be preferred in managing advanced tongue and mouth floor SCC [@B58]. Even though, severe dermatitis and mucositis may occur within the radiation field during IACRT treatment, these toxicities were manageable and can be recovered by drug or professional oral management [@B59]. Other studies reported that mucositis and dysphagia were regarded to be inevitable but reversible [@B14], [@B32]. Additionally, systemic toxicities such as anemia, thrombocytopenia and leukopenia were also reported before [@B60]-[@B62]. Here, we summarized ten toxicities from the 34 studies, including oral diseases, mucositis, leukopenia, dermatitis, anemia, general condition, thrombocytopenia, nausea/vomiting, fever and hepatic dysfunction. All of them were manageable and reversible. Oral diseases, mucositis, dermatitis and leukopenia were the major toxicities with relatively high incidence. Therefore, more attention should be paid to prevent these toxicities for more favorable outcomes.

The limitations of our meta-analysis should be taken into account when interpreting the results. Firstly, among the included 34 studies, only one study is RCT, due to clinically inoperable, most studies did not have control group. Therefore, the results of these studies were incomparable. Secondly, most studies were conducted in Japan, only 7 studies were conducted in other countries, this may bring both regional and cultural bias. Thirdly, the investigation sample size of some studies was small, which would increase the heterogeneity of our study.

In conclusion, the results of this study suggested that IACRT is an efficient and safe therapy for HNC with manageable toxicities, especially for advanced HNC with stage III or T3. The toxicities such as oral diseases, mucositis, leukopenia, dermatitis, general condition and anemia should be concerned during treatment. However, due to the limitations of clinical studies and the differences in IACRT methods, more high-level and large-sample clinical trials are needed to further confirm the efficacy of ICART in the comprehensive treatment for HNC.
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###### 

Characteristics of enrolled studies.

  Study               Year         Study design          Cancer type                         Age             Male (%)   T classification   Sample size   Follow-up (y)   Country     Outcome measured
  ------------------- ------------ --------------------- ----------------------------------- --------------- ---------- ------------------ ------------- --------------- ----------- ------------------
  Arcangeli [@B18]    1983         RCT                   SCC                                 \-              \-         T2-T4              142           5               Italy       5-y OS
  Fujishiro [@B19]    2007         Retrospective study   Maxillary sinus carcinoma           62              78.6       T2-T4b             14            2.1             Japan       CR, 3-y OS
  Furusaka [@B20]     2012         Retrospective study   Tongue SCC                          66.4\[37-81\]   75.6       T2-T4b             45            3.2             Japan       CR, 5-y OS
  Furusaka [@B21]     2013         Retrospective study   Hypopharyngeal piriform sinus SCC   64.1\[37-74\]   93         T3-T4b             57            5.3             Japan       CR, 5-y OS
  Furusaka [@B22]     2013         Retrospective study   Oropharyngeal SCC                   64.6\[37-86\]   74.5       T2-T4b             51            5               Japan       CR,5-y OS
  Fuwa [@B16]         2008         Retrospective study   Tongue cancer                       68\[25-87\]     65         T2-T4              40            2.3             Japan       CR,5-y OS
  Fuwa [@B23]         2008         Retrospective study   Tongue SCC                          63\[25-87\]     71.6       T2-T4b             88            4.4             Japan       CR,3-y OS
  Fuwa [@B24]         2008         Retrospective study   OSCC                                67\[25-89\]     66.4       T2-T4b             134           3.8             Japan       CR,3-y OS
  Hayashi [@B25]      2017         Retrospective study   OSCC                                82.5\[80-88\]   38.7       T2-T4b             31            3.1             Japan       CR,3-y OS
  Homma [@B26]        2016         Retrospective study   Hypopharyngeal cancer               60.6\[45-75\]   96.7       T1-T4b             92            5.2             Japan       5-y OS
  Kobayashi [@B27]    2010         Prospective study     OSCC                                61.7            63.6       T2-T4              22            1.5             Japan       CR,5-y OS
  Kondo [@B28]        2016         Retrospective study   OSCC                                68\[58-82\]     77.8       T3, T4a            18            5               Japan       CR,3-y OS
  Kovacs [@B15]       2004         Retrospective study   Oral and oropharynx cancer.         66\[38-89\]     53.8       T1-T4              52            5               Germany     CR,3-y OS,5-y OS
  Minamiyama [@B29]   2017         Retrospective study   Tongue SCC                          63.5\[34-87\]   69         T2-T4a             42            3.9             Japan       CR,3-y OS,5-y OS
  Mitsudo [@B9]       2014         Retrospective study   OSCC                                59\[28-87\]     69.6       T2-T4b             112           3.9             Japan       CR,3-y OS,5-y OS
  Mitsudo [@B14]      2018         Retrospective study   Tongue SCC.                         61\[25-87\]     66.1       T2-T4b             118           3.2             Japan       CR,3-y OS,5-y OS
  Miyawaki [@B30]     2012         Retrospective study   OSCC                                69\[39-84\]     57.5       T1-T4              40            6.8             Japan       CR, 5-y OS
  Mukai [@B31]        2014         Retrospective study   Gingival carcinoma                  74\[50-93\]     61.8       T1-T4b             34            3               Japan       CR,3-y OS,5-y OS
  Takayama [@B32]     2016         Retrospective study   Tongue SCC                          53\[25-69\]     66.7       T2-T4a             33            3.6             Japan       CR,3-y OS
  Tsukahara [@B33]    2008         Retrospective study   Oropharyngeal SCC                   63.1\[44-85\]   \-         T1-T4              73            5               Japan       5-y OS
  Yoshizaki [@B34]    2007         Prospective study     HNSCC                               61.2 ± 13.8     91.8       T2-T4              49            2               Japan       CR,3-y OS
  Yoshizaki [@B35]    2009         Retrospective study   Laryngeal Cancer                    63.9            92.7       T2-T4              41            3               Japan       CR,3-y OS
  Bertino [@B36]      2007         Retrospective study   HNSCC                               39-75           93.5       T2-T4              46            5               Italy       CR, 5-y OS
  Bertino [@B37]      2009         Retrospective study   HNSCC                               38-74           82.1       T1-T4              56            2               Italy       CR
  Doi [@B38]          2018         Retrospective study   MSSCC                               63.5\[31-82\]   16.7       T3-T4b             24            4.8             Japan       CR,3-y OS
  Doweck [@B39]       2008         Retrospective study   OSCC                                58              81.9       T3-T4              155           \-              USA         5-y OS
  Hayashi [@B40]      2019         Retrospective study   Gingival SCC                        \-              46.0       T2-T4b             46            3.3             Japan       CR,3-y OS
  Homma [@B41]        2013         Prospective study     MSSCC                               35-74           79.6       T2-T4b             54            6.4             Japan       CR,5-y OS
  Kim [@B42]          2013         Retrospective study   Maxillary sinus carcinoma           57\[32-73\]     92.6       T3-T4              27            6.4             Korea       5-y OS
  Krstevska [@B43]    2012         Retrospective study   Oropharyngeal SCC                                   90.8       T2-T4              65            1.2             Macedonia   CR
  Nakashimaa [@B44]   2011         Retrospective study   Maxillary sinus carcinoma           37-67           60.0       T4a-T4b            5             2               Japan       CR
  Nozato [@B45]       2019         Retrospective study   OSCC                                55\[35-81\]     61.5       T2-T4b             26            5               Japan       CR,5-y OS
  Takahara [@B46]     2017         Retrospective study   NNKTL                               53\[21-70\]     83.3       \-                 12            6.8             Japan       CR
  Yokoyama [@B47]     2014         Retrospective study   Paranasal sinus cancer              66.5\[45-84\]   76.1       T3-T4b             46            3.1             Japan       CR
  Total               34 studies                                                                                                           1890                                      

RCT: randomized controlled trial; SCC: squamous cell carcinoma; OSCC: oral squamous cell carcinoma; HNSCC: head and neck squamous cell carcinoma; MSSCC: maxillary sinus squamous cell carcinoma; NNKTL: nasal natural killer/T-cell lymphoma; CR: complete response; 3-y OS: 3-year overall survival; 5-y OS: 5-year overall survival.

###### 

Analytic results of toxicities.

  Toxicity              Incidence   95% CI        Number of studies Included
  --------------------- ----------- ------------- ----------------------------
  Oral diseases         0.515       0.266-0.765   10
  Mucositis             0.589       0.417-0.762   21
  Leukopenia            0.401       0.297-0.504   22
  Dermatitis            0.434       0.235-0.633   14
  Anemia                0.318       0.187-0.450   20
  General condition     0.339       0.202-0.475   13
  Thrombocytopenia      0.245       0.150-0.341   17
  Nausea/vomiting       0.263       0.152-0.374   13
  Fever                 0.117       0.057-0.177   8
  Hepatic dysfunction   0.064       0.021-0.107   7
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